Comparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitus
dc.contributor.author | Mohammad, Anjoom | en_US |
dc.contributor.author | Chand, Miyan Kamaal | en_US |
dc.contributor.author | Beg, Mirza Atif | en_US |
dc.contributor.author | Bawa, Shalu | en_US |
dc.date.accessioned | 2020-09-24T07:10:54Z | |
dc.date.available | 2020-09-24T07:10:54Z | |
dc.date.issued | 2019-09 | |
dc.description.abstract | Introduction: This study assumes significance as it compareshead on DPP-IV inhibitors along with other oral hypoglycemicagents with respect to glycemic and non-glycemic targets.Study was done to evaluate the DPP-IV inhibitors andother oral hypoglycemic agents (OHA) either alone or incombination, with reference to glycemic targets like fastingplasma glucose (FPG), post prandial glucose (PPG) andglycosylated hemoglobin (HbA1c) in type 2 diabetes mellitus.Material and Methods: This was an open labelledcomparative study and included 90 patients with Type 2 DM.These patients were divided into 3groups: Each group wascontaining 30 patients i.e. Group A: DPP-IV inhibitors (n=30); Group B: Oral hypoglycemic agents other than DPP-IVinhibitors (n= 30) and Group C: DPP-IV inhibitors + other oralhypoglycemic agents (n= 30). The patients were given drugson the basis of physician’s discretion, depending upon theglycemic of the patients at the time of presentation. A detailedhistory regarding age, sex, profession, duration of disease,treatment history, family history and personal history wastaken for each patient. After stabilization patients observed at0 weeks, 6 weeks, 12 weeks and 24 weeks.Results: Mean duration of diabetes was 5.35±0.53 years, andthe mean age of onset of diabetes was 46.98±0.91years. Therewas no significant difference between the study groups withrespect to FPG, PPG, and HbA1c levels. The HbA1c showedsignificant improvement in each group at the end of studyperiod.Conclusion: In summary, this study showed that treatmentwith sitagliptin, either alone or in combination with other oralhypoglycemic agent led to clinically meaningful reductionsin HbA1c, FPG and PPG over a 24 week period. Sitagliptinpresents an alternative therapeutic strategy for patientswith type 2 diabetes and, in general, showed significantimprovements in glycemic control and is well tolerated,particularly with regard to weight change and hypoglycemia. | en_US |
dc.identifier.affiliations | Assistant Professor, Department of Pharmacology and Therapeutics, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College, Saharanpur, Uttar Pradesh | en_US |
dc.identifier.affiliations | Associate Professor, Department of Pharmacology and Therapeutics, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College, Saharanpur, Uttar Pradesh | en_US |
dc.identifier.affiliations | Professor, Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun Uttarakhand | en_US |
dc.identifier.affiliations | Associate Professor, Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, India | en_US |
dc.identifier.citation | Mohammad Anjoom, Chand Miyan Kamaal, Beg Mirza Atif, Bawa Shalu. Comparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitus. International Journal of Contemporary Medical Research . 2019 Sep; 6(9): i5-i11 | en_US |
dc.identifier.issn | 2393-915X | |
dc.identifier.issn | 2454-7379 | |
dc.identifier.place | India | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/202549 | |
dc.language | en | en_US |
dc.publisher | International Society for Contemporary Medical Research | en_US |
dc.relation.issuenumber | 9 | en_US |
dc.relation.volume | 6 | en_US |
dc.source.uri | https://dx.doi.org/10.21276/ijcmr.2019.6.9.23 | en_US |
dc.subject | Diabetes Mellitus | en_US |
dc.subject | Oral Hypoglycemic Agents | en_US |
dc.subject | PP-IV Inhibitors | en_US |
dc.subject | Glycaemic Control | en_US |
dc.subject | Glycosylated hemoglobin | en_US |
dc.title | Comparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitus | en_US |
dc.type | Journal Article | en_US |
Files
Original bundle
1 - 1 of 1